## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: Bunner, Bridget E.
Kevin P. BAKER, et al.	) Art Unit: 1647
Application Serial No. 10/015,822	) Confirmation No: 8184
Filed: December 10, 2001	) Attorney's Docket No. 39780-2830 P1C38
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	) Customer No. 35489 ) )

EXPRESS MAIL LABEL NO. <u>EV 582 628 195 US</u>

DATE MAILED: FEBRUARY 2, 2005

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

## MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

02/09/2005 AWONDAF1 00000033 081641 10015822

01 FC:1806

180.00 DA

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):								
	(1) It is being filed within 3 months of the application filing date and is of than a continued prosecution application under § 1.53(d)  OR						er		
			(2)	It is being filed	l within 3 mo	onths of ent	ry of a natio	onal stage	
			(3) merits	It is being filed	l before the r	nail date of	the first Of	fice Action on the	
			(4) of a req	OR It is being filed uest for continu				Action after the filing	3
	37 C.F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.11$ or a notice of allowance under $\S1.311$ , then:						e		
		a certific	cation as	s specified in §1	1.97(e) is pro	vided belov	v; or		
				as set forth in other papers file				sed, or included with	
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a fin office action under §1.113 or a notice of allowance under §1.311, but before payment of the is fee, then:								e
	A.	a certification as specified in §1.97(e) is completed below; and							
	В.	B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and							
	C.	a fee of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.							
Fee Authorization. The Commissioner is hereby authorized to charge the of \$180.00 and charge any additional fees or credit any overpayment assembly communication to Deposit Account No. 08-1641 (Attorney's Docket No. 08-1641)						ment assoc	iated with this		
	,				Respectful	ly submitted	l,		
Dated:	Februar	ry 2, 2005	5		By:	L. Barry (R	) eg. No. 51,4	436)	
275 Mi Menlo Telepho	ddlefield Park, Ca one: (65		94025-3 000	& McAULIFF	E LLP				

-2-

PTO/SB/08 (2/92) Sheet 1 of 1

Form PTO-1449				Attorney's Docket No. 39780-2830 P1C38		Application Serial No. 10/015,822				
INFO	RMATI	ON DISCLO	SURE STATEMENT	Applicant(s) Kev	in P. BAKER,	et al.				
(use several sheets if necessary)				Filing Date: December 10, 2001	Gro	Group Art Unit:				
	.359			U.S. PATENT DOCUMENTS		, - 4		31 - F4		
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)			
	<u> </u>		F(	DREIGN PATENT DOCUMENTS	42 3245 mg	i da	1, 1			
Examiner			Document No.	Name	Class	Subclass	Translation			
Initials	No.			(3)			YES	NO		
* 3	-		(including	OTHER DOCUMENTS  g author, title, date, pertinent pages, et	c.)	i i i i i i i i i i i i i i i i i i i	HALL TANKS			
Examiner Initials	Ref. No.	Title								
	1.	Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999).								
	2.	Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer <sup>1,2</sup> ", <i>Cancer Research</i> – 62:6240-6245 (2002)								
	3.	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non- Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular &amp; Cellular Proteomics</i> - 1:37-45 (2002)								
	4.	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors", <i>PNAS</i> – 99(20):12963-12968 (2002)								
•	ļ	Transcrip		III Breast Tumors , FNAS = <u>99(20)</u> .1290	35-12900 (2002)					
•	ļ									
•	-	-								
	1	<u> </u>			· · · · · · · · · · · · · · · · · · ·					
,	<del> </del>	<del></del>	· · · · · · · · · · · · · · · · · · ·							

EXAMINER:	DATE	CON	SIDERE	.D:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2094704 v1